Q3 2020 Sales Performance

Preparing for 2 new companies gsk Investment in R&D and future growth drivers 2-year separation programme New GSK New CH Common approach to R&D and capital allocation Capabilities and efficiencies in support functions Optimise supply chain and portfolio. Divestments Build key technology infrastructure and corporate functions New GSK: a leading biopharma company with R&D focused on science of the immune system, genetics and advanced technologies CH JV integration, synergy delivery and investment in growth drivers New leading Consumer Healthcare company with category leading power brands and innovation based on science and consumer insights 7

View entire presentation